Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4

References

• BRADFORD, M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein—dye binding. Analytical Biochemistry,72, 248–254.
   PubMed Web of Science ®Google Scholar
• BREIMER, D. D., 1995, An integrated molecular and kinetic/dynamic approach to metabolism in drug development. In European Cooperation in the Field of Scientific and Technical Research . COST B1 Conference on Variability and Speciftcity in Drug Metabolism (Brussels: European Commission), 2–19
   Google Scholar
• DISLERATH, L. M., REILLY, P. E., MARTIN, M. V., DAVIS, G. G., WILKINsoN, G. R. and GUENGERICH F. P., 1985, Purification and characterization of the human liver cytochrom es P-450 involved in debrisoquine 4-hydroxylation and phenacetin 0-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism .Journal of Biological Chemistry, 260, 9057–9067.
   Google Scholar
• ENGELHARDT, G., BoGEL, R., SCHNITZLER, C. and UTZMANN, R., 1995a, Meloxican: influence 011 arachidonic acid metabolism. Part II: In vivo findings. Biochemical Pharmacology, 51, 21–38.
   Web of Science ®Google Scholar
• ENGELHARDT, G., HOMMA, D., SCHLEGEL, K., UTZMANN, R. and SCHNITZLER, C., 1995b, Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflammation Research, 44, 423–433.
   PubMed Web of Science ®Google Scholar
• GOLSTEIN, J. A. and DE MORAIS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetic s, 4,285–299.
   PubMedGoogle Scholar
• GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLF, T. and WAXMAN, D. J., 1986, Characterizaticn of rat and human liver microsomal cytochrome P-450 forms involved in nifedipineoxidation,a prototype for genetic polymorphismin oxidative drug metabolism Journal of Biological Chemistry,261, 5051–5060.
   PubMed Web of Science ®Google Scholar
• GUGUEN -GUILLOUZO, C. and GuILLouzo, A., 1986, Methods for preparation of adult and fetal hepatocytes. In Isolated and Cultured Hepatocytes, edited by A. Guillouzo and C. Guguen-Guillouzo (Paris and London: IN SERM and John Libbey Eurotext), pp. 1–12.
   Google Scholar
• GUILLOUZO, A. and CHESNE, C., 1996, Xenobiotic metabolism in epithelial cell cultures.. In Epithelial Cell Culture: A Practical Approach, edited by A. J. Shaw (Oxford: IRL), pp. 67–85.
   Google Scholar
• HOSIE, J., DISTEL, M. and BLumnu, E., 1996, Meloxicam in osteoarthritis: a 6-month double blind comparison with diclofenac sodium. British Journal of Rheumatology,, 35 (suppl 1), 39–43.
   PubMedGoogle Scholar
• ICHIHARA, S., TOMISAWA, H., FUKAZAWA, H. and TATEISHI, M., 1985, Involvement of leucocyte peroxidases in the metabolism of tenoxicam. Biochemical Pharmacology, 34, 1337–1338.
   PubMed Web of Science ®Google Scholar
• KLOTZ, A. V., STEGEMAN J. J. and WALSH, C., 1984, An alternative 7-ethoxyresorufin 0-deethylase activity assay: a continuous visible spectrophotometric method for measurement of cytochrome P-450 monooxygenase activity. Analytical Biochemistry, 140, 138–145.
   Google Scholar
• KOOP D. R., 1986, Hydroxylation of p-nitrophenol by rabbit ethanol inducible cytochrome P-450 isozyme IIIa. Molecular Pharmacology, 29, 399–404.
   PubMed Web of Science ®Google Scholar
• KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. and MEYER, U. A., 1987, High-performance liquid chromatographic assays for bufuralol 1-hydroxylase, debrisoquine 4-hydroxylase, and dextro-methorphan 0-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Analytical Biochemistry, 162, 24–32.
   PubMed Web of Science ®Google Scholar
• MINERS, J. 0., Rs, D. L. P., VALENTE L., VERONESE, M. E. and BIRKETT, D. J., 1995, Human hepatocyte cytochrome P-450 2C9 catalyzes the rate limiting pathway of torsemide metabolism. Journal of Pharmacology and Experimental Therapeutics, 272, 1076–1081.
   Google Scholar
• MITCHELL, J. A., AKARASEREENONT, P., TH1ERMERMANN, C., FLOWER, R. J. and VANE, J. R., 1994, Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences, USA, 90, 11693–11697.
   Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONAZALEZ, F. J. and TSUTSUI, T., 1996, Specificityof substrate and inhibitor probes for cytochromes P450s: evaluation of in vitro metabolism using cD NA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• REGINSTER, J. Y., DISTEL, M. and BLummu, E., 1996, A double blind three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. British Journal of Rheumatology,, 35 (Suppl 1), 17–21.
   PubMedGoogle Scholar
• RETTlE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. C., AOYAMA, T., GELBOIN H. V., GONZALEZ, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cD NA-expressed cytochrome P-450: A role for P-450C29 in the etiology of (S)-warfarin drug interactions. Chemical Research of Toxkology,, 5, 54–59.
   Google Scholar
• ROMKES, M., FALETTO, M. B., BLAISDELL, J. A., RAUCY, J. L. and GOLDSTEIN, J. A., 1991, Cloning and expression of complementaryDNAs for multiple members of the human cytochrome P-450I1C. Biochemistry, 30, 3247–3255.
   PubMed Web of Science ®Google Scholar
• SCHMID, J., BUSCH ., U., TRUMMLITZ, G., PROX, A., KASCHKE, S. and WACHSMUTH, H., 1995a, Meloxicam: metabolic profile and biotransformation products in the rat. Xenobiotka, 25, 1219–1236.
   Google Scholar
• SCHMID, J., Buscu, U., HEINZEL, G., BOZLER, G., KASCHKE, S. and KUMMER, M., 1995b, Meloxicam: pharmacokineties and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metabolism and Disposition,23, 1206–1213.
   PubMed Web of Science ®Google Scholar
• SCHMID, J. and ROTH, W.,1987, HPL C-procedure for drug metabolism studies: the potential of column switching. In Drug Metabolism, From Molecules to Man, edited by D. J. Benford, J. W. Bridges and C. G. Gibson (London: Taylor & Francis), pp. 213–216.
   Google Scholar
• SEIBERT, K., ZHANG, Y., LEAHY, K., HAUSER, S., MASFERRER, J., PERKINS, W., LEE, L. and ISAKSON, P., 1994. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammationand pain. Proceedings of the National Academy of Sciences, USA, 91,12013–12017.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., MISONO, S. K. and GUENGERICH, F. P., 1986. Human liver microsomalcytochrome P-450 mephenytoin4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 261, 909–921.
   PubMed Web of Science ®Google Scholar
• STUBBINS, M. J., HARRIES, L. W., SMITH, G., TARBIT, M. H. and WOLF, C. R., 1996, Genetic analysis of the human cytochrome P-450 CYP2C 9 locus. Pharmacogenetk s, 6, 432–439.
   Google Scholar
• SULLIVAN -KLOSE, T. H.,GHANAYEM, B. I., BELL, D.A., ZHANG, Z. Y., KAMINSKY, L. S.,SHENFIELD, G. M., MINERS, J. 0., BIRKETT, D. J. and GOLDSTEIN, J. A., 1996. The role of CYP2C9-Leu3"' allelic variant in the tolbutamide polymorphism .Pharmacogerzetk s, 6, 341–349.
   Google Scholar
• TURCK, D., Su, C. A. P. F., HEINZEL, G., Busuu, U., BLuumiu, E. and HOFFMANN, J., 1997, Lack of interaction between meloxicam and warfarin in healthy volunteers. European Journal of Clinical Pharmacology, 51, 421–425.
   Google Scholar
• ZHAO, J., LEEMANN, T. and DAYER, P., 1992, In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P-450. Life Sciences, 51, 575–581.
   PubMed Web of Science ®Google Scholar